Search

Your search keyword '"Routy B"' showing total 239 results
Start Over Author "Routy B"
239 results on '"Routy B"'

3. T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants

Author

Messaoudene, M., Mourikis, T.P., Michels, J., Fu, Y., Bonvalet, M., Lacroix-Trikki, M., Routy, B., Fluckiger, A., Rusakiewicz, S., Roberti, M.P., Cotteret, S., Flament, C., Poirier-Colame, V., Jacquelot, N., Ghiringhelli, F., Caignard, A., Eggermont, A.M.M., Kroemer, G., Marabelle, A., Arnedos, M., Vicier, C., Dogan, S., Jaulin, F., Sammut, S -J, Cope, W., Caldas, C., Delaloge, S., McGranahan, N., André, F., and Zitvogel, L.

Published
2019
Full Text
View/download PDF

4. MA16.06 Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study

Author

Wheatley-Price, P., primary, Navani, V., additional, Pabani, A., additional, Routy, B., additional, Snow, S., additional, Denault, M.-H., additional, Kim, Y., additional, Syed, I., additional, Devost, N., additional, Hui, D., additional, Arora, P., additional, Velummailum, R., additional, Springford, A., additional, McKibbon, C., additional, and Ho, C., additional

Published
2023
Full Text
View/download PDF

7. A47 THE GUT MICROBIOTA INFLUENCES COLONIC HEALING AFTER SURGERY IN PATIENTS UNDERGOING BOWEL RESECTION FOR COLORECTAL CANCER

Author

Hajjar, R, primary, Gonzalez, E, additional, Fragoso, G, additional, Oliero, M, additional, Alaoui, A A, additional, Calvé, A, additional, Vennin Rendos, H, additional, Djediai, S, additional, Cuisiniere, T, additional, Laplante, P, additional, Gerkins, C, additional, Ajayi, A S, additional, Diop, K, additional, Taleb, N, additional, Thérien, S, additional, Schampaert, F, additional, Alratrout, H, additional, Dagbert, F, additional, Loungnarath, R, additional, Sebajang, H, additional, Schwenter, F, additional, Wassef, R, additional, Ratelle, R, additional, Debroux, E, additional, Cailhier, J -F, additional, Routy, B, additional, Annabi, B, additional, Brereton, N, additional, Richard, C, additional, and Santos, M M, additional

Published
2023
Full Text
View/download PDF

11. 259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota

Author

Derosa, L., primary, Alves Costa Silva, C., additional, Iebba, V., additional, Routy, B., additional, Reni, A., additional, Audigier-Valette, C., additional, Zalcman, G., additional, Mazieres, J., additional, Friard, S., additional, Goldwasser, F., additional, Moro-Sibilot, D., additional, Scherpereel, A., additional, Pegliasco, H., additional, Martinez, S., additional, Escudier, B., additional, Planchard, D., additional, Albiges, L., additional, Besse, B., additional, Barlesi, F., additional, and Zitvogel, L., additional

Published
2022
Full Text
View/download PDF

15. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)

Author

Auclin, E., primary, Benitez-Montanez, J., additional, Gorria, T., additional, Garcia-Campelo, R., additional, Dempsey, N., additional, Pinato, D.J., additional, Reyes, R., additional, Albarran, V., additional, Dall'ollio, F., additional, Soldato, D., additional, Hendriks, L., additional, Aboubakar, F., additional, Tonneau, M., additional, Lopez-Castro, R., additional, Nadal, E., additional, Katsandjian, S., additional, Blanc-Durand, F., additional, Fabre, E., additional, Castro, N., additional, Arasanz, H., additional, Muanza, T., additional, Rochand, A., additional, Besse, B., additional, Routy, B., additional, and Mezquita, L., additional

Published
2022
Full Text
View/download PDF

17. EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront

Author

Torres Jiménez, J., primary, Gorria, T., additional, Auclin, E., additional, Castro, N., additional, Albarrán-Artahona, V., additional, Ruffinelli, J.C., additional, Pinato, D., additional, Routy, B., additional, Aboubakar Nana, F., additional, Reyes, R., additional, Viñolas, N., additional, Blanc-Durand, F., additional, Lopes, G., additional, Nadal, E., additional, Arasanz, H., additional, Pascal, M., additional, Teixidó, C., additional, Besse, B., additional, Reguart, N., additional, Mezquita, L., additional, and Torres Jiménez, J., additional

Published
2022
Full Text
View/download PDF

18. EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront

Author

Gorria, T., primary, Torres-Jiménez, J., additional, Auclin, E., additional, Castro, N., additional, Albarrán-Artahona, V., additional, Ruffinelli, J.C., additional, Pinato, D., additional, Routy, B., additional, Nana, F. Aboubakar, additional, Reyes, R., additional, Viñolas, N., additional, Teixidó, C., additional, Blanc-Durand, F., additional, Planchard, D., additional, Lopes, G., additional, Nadal, E., additional, Arasanz, H., additional, Pascal, M., additional, Prat, A., additional, Reguart, N., additional, Besse, B., additional, and Mezquita, L., additional

Published
2022
Full Text
View/download PDF

20. 1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)

Author

Elkrief, A., Duttagupta, S., Jamal, R., Marcoux, N., Desilets, A., Messaoudene, M., Mihalcioiu, C., Durand, S., Tehfe, M., Blais, N., Owen, S., Raphael, J., Lenehan, J.G., Parvathy, S.N., Derosa, L., Zitvogel, L., Kroemer, G., Silverman, M., Maleki Vareki, S., and Routy, B.

Published
2024
Full Text
View/download PDF

21. EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront

Author

UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Gorria, T., Torres-Jiménez, J., Auclin, E., Castro, N., Albarrán-Artahona, V., Ruffinelli, J.C., Pinato, D., Routy, B., Aboubakar Nana, Frank, Reyes, R., Viñolas, N., Teixidó, C., Blanc-Durand, F., Planchard, D., Lopes, G., Nadal, E., Arasanz, H., Pascal, M., Prat, A., Reguart, N., Besse, B., Mezquita, L., UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Gorria, T., Torres-Jiménez, J., Auclin, E., Castro, N., Albarrán-Artahona, V., Ruffinelli, J.C., Pinato, D., Routy, B., Aboubakar Nana, Frank, Reyes, R., Viñolas, N., Teixidó, C., Blanc-Durand, F., Planchard, D., Lopes, G., Nadal, E., Arasanz, H., Pascal, M., Prat, A., Reguart, N., Besse, B., and Mezquita, L.

Published
2022

22. EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront

Author

UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Torres Jiménez, J., Gorria, T., Auclin, E., Castro, N., Albarrán-Artahona, V., Ruffinelli, J.C., Pinato, D., Routy, B., Aboubakar Nana, Frank, Reyes, R., Viñolas, N., Blanc-Durand, F., Lopes, G., Nadal, E., Arasanz, H., Pascal, M., Teixidó, C., Besse, B., Reguart, N., Mezquita, L., UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Torres Jiménez, J., Gorria, T., Auclin, E., Castro, N., Albarrán-Artahona, V., Ruffinelli, J.C., Pinato, D., Routy, B., Aboubakar Nana, Frank, Reyes, R., Viñolas, N., Blanc-Durand, F., Lopes, G., Nadal, E., Arasanz, H., Pascal, M., Teixidó, C., Besse, B., Reguart, N., and Mezquita, L.

Published
2022

23. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)

Author

UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Auclin, E., Benitez-Montanez, J., Gorria, T., Garcia-Campelo, R., Dempsey, N., Pinato, D.J., Reyes, R., Albarran, V., Dall'ollio, F., Soldato, D., Hendriks, L., Aboubakar Nana, Frank, Tonneau, M., Lopez-Castro, R., Nadal, E., Katsandjian, S., Blanc-Durand, F., Fabre, E., Castro, N., Arasanz, H., Muanza, T., Rochand, A., Besse, B., Routy, B., Mezquita, L., UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Auclin, E., Benitez-Montanez, J., Gorria, T., Garcia-Campelo, R., Dempsey, N., Pinato, D.J., Reyes, R., Albarran, V., Dall'ollio, F., Soldato, D., Hendriks, L., Aboubakar Nana, Frank, Tonneau, M., Lopez-Castro, R., Nadal, E., Katsandjian, S., Blanc-Durand, F., Fabre, E., Castro, N., Arasanz, H., Muanza, T., Rochand, A., Besse, B., Routy, B., and Mezquita, L.

Abstract

INTRODUCTION : The combination of IO-CT has become the standard of care for patients with aNSCLC with a low or intermediate programmed death-ligand 1 (PD-L1) expression (<50%), and an option for patients with high PDL1 (≥50%) expression. There are no data available on the subsequent line (L2) outcomes after IO-CT. We aimed to assess the outcomes of various L2 treatments after IO-CT in aNSCLC. [...]

Published
2022

24. Prospective Neurocognitive Functions of Patients Treated With Concurrent Nivolumab and Stereotactic Brain Radiosurgery for NSCLC and RCC Brain Metastases

Author

Masucci, G.L., primary, Boucher, O., additional, Marie, F., additional, Plourde, M.E., additional, Panet-Raymond, V., additional, Pavic, M., additional, Owen, S., additional, Masson-Cote, L., additional, Menard, C., additional, Routy, B., additional, Tehfe, M., additional, Blais, N., additional, Roberge, D., additional, and Wong, P., additional

Published
2021
Full Text
View/download PDF

25. 1357P A deep radiomics approach to assess PD-L1 expression and clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A multicentric study

Author

Tonneau, M., primary, Phan, K., additional, Kazandjian, S., additional, Elkrief, A., additional, Panasci, J., additional, Richard, C., additional, Nolin-Lapalme, A., additional, El Sayed, R., additional, Ding, L., additional, Nair, T., additional, Malo, J., additional, Chandelier, F., additional, Kafi, K., additional, O'Brien, J., additional, Di Jorio, L., additional, Muanza, T., additional, and Routy, B., additional

Published
2021
Full Text
View/download PDF

27. Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront [FP07.06]

Author

Blanc-Durand, F., Mielgo Rubio, X., Auclin, E., Ponce-Aix, S., Lopez Castro, R., Nadal, E., Planchard, D., Routy, B., Hendriks, L., Sullivan, I., Dempsey, N., Pilotto, S., Aboubakar Nana, Frank, Pinato, D.J., Castonguay, M., Rodriguez, A., Amores, A., Bluthgen, M.V., Duchemann, B., Castellano, P. Cruz, Aguado De La Rosa, C., Sereno Moyano, M., Ruffinelli, J., Lopez, G., Caramella, C., Besse, B., Mezquita, L., 2020 World Conference on Lung Cancer, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (SLuc) Service de pneumologie

Subjects
Pulmonary and Respiratory Medicine, Oncology
Abstract

INTRODUCTION : The Lung Immune Prognostic Index (LIPI) that combines the neutrophils/[leucocytes minus neutrophils] ratio (dNLR) and lactate dehydrogenase (LDH), is associated with outcomes in pretreated advanced NSCLC patients receiving single agent immune checkpoint inhibitors (ICI). However, its role in first line treatment of advanced NSCLC patients has not been explored yet. We assessed the value of baseline LIPI in the first line setting, for ICI-monotherapy, ICI-combination or platinum-based chemotherapy alone (CT). [...]

Published
2021

28. Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront [FP07.06]

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Blanc-Durand, F., Mielgo Rubio, X., Auclin, E., Ponce-Aix, S., Lopez Castro, R., Nadal, E., Planchard, D., Routy, B., Hendriks, L., Sullivan, I., Dempsey, N., Pilotto, S., Aboubakar Nana, Frank, Pinato, D.J., Castonguay, M., Rodriguez, A., Amores, A., Bluthgen, M.V., Duchemann, B., Castellano, P. Cruz, Aguado De La Rosa, C., Sereno Moyano, M., Ruffinelli, J., Lopez, G., Caramella, C., Besse, B., Mezquita, L., 2020 World Conference on Lung Cancer, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Blanc-Durand, F., Mielgo Rubio, X., Auclin, E., Ponce-Aix, S., Lopez Castro, R., Nadal, E., Planchard, D., Routy, B., Hendriks, L., Sullivan, I., Dempsey, N., Pilotto, S., Aboubakar Nana, Frank, Pinato, D.J., Castonguay, M., Rodriguez, A., Amores, A., Bluthgen, M.V., Duchemann, B., Castellano, P. Cruz, Aguado De La Rosa, C., Sereno Moyano, M., Ruffinelli, J., Lopez, G., Caramella, C., Besse, B., Mezquita, L., and 2020 World Conference on Lung Cancer

Abstract

INTRODUCTION : The Lung Immune Prognostic Index (LIPI) that combines the neutrophils/[leucocytes minus neutrophils] ratio (dNLR) and lactate dehydrogenase (LDH), is associated with outcomes in pretreated advanced NSCLC patients receiving single agent immune checkpoint inhibitors (ICI). However, its role in first line treatment of advanced NSCLC patients has not been explored yet. We assessed the value of baseline LIPI in the first line setting, for ICI-monotherapy, ICI-combination or platinum-based chemotherapy alone (CT). [...]

Published
2021

31. FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.

Author

Blanc-Durand, F., primary, Mielgo Rubio, X., additional, Auclin, E., additional, Ponce-Aix, S., additional, Lopez Castro, R., additional, Nadal, E., additional, Planchard, D., additional, Routy, B., additional, Hendriks, L., additional, Sullivan, I., additional, Dempsey, N., additional, Pilotto, S., additional, Aboubakar, F., additional, Pinato, D.J., additional, Castonguay, M., additional, Rodriguez, A., additional, Amores, A., additional, Bluthgen, M.V., additional, Duchemann, B., additional, Castellano, P. Cruz, additional, Aguado De La Rosa, C., additional, Sereno Moyano, M., additional, Ruffinelli, J., additional, Lopez, G., additional, Caramella, C., additional, Besse, B., additional, and Mezquita, L., additional

Published
2021
Full Text
View/download PDF

32. Erratum: Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020

Author

Elkrief, A., Joubert, P., Florescu, M., Tehfe, M., Blais, N., and Routy, B.

Subjects
Canada, Lung Neoplasms, Article Doi, small cell, History, 21st Century, landscape of metastatic, cell lung, Therapeutic Landscape, Carcinoma, Non-Small-Cell Lung, Humans, 10.3747/co.27.5953, Immunotherapy, Neoplasm Metastasis, Erratum
Abstract

Lung cancer is the most commonly diagnosed cancer in Canada and remains associated with high mortality. Nevertheless, recent advances in the fields of immuno-oncology and precision medicine have led to significant improvements in clinical outcome in metastatic non-small-cell lung cancer (nsclc). Those improvements were facilitated by a greater understanding of the biologic classification of nsclc, which catalyzed discoveries of novel therapies. Here, we present a comprehensive review of the recent avalanche of practice-changing trials in metastatic nsclc, and we offer an approach to the management of this disease from a Canadian perspective. We begin with an overview of the pathologic and molecular characterization of metastatic nsclc. Next, we review the indications for currently approved immune checkpoint inhibitors, and we provide an approach to the management of disease with a driver mutation. Finally, we address future avenues in both diagnostics and therapeutics for patients with advanced and metastatic nsclc.

Published
2020
Full Text
View/download PDF

33. Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy

Author

Daillere, R., Derosa, L., Bonvalet, M., Segata, N., Routy, B., Gariboldi, M., Budinska, E., Vries, I.J.M. de, Naccarati, A.G., Zitvogel, V., Caldas, C., Engstrand, L., Loilbl, S., Fieschi, J., Heinzerling, L., Kroemer, G., Zitvogel, L., Daillere, R., Derosa, L., Bonvalet, M., Segata, N., Routy, B., Gariboldi, M., Budinska, E., Vries, I.J.M. de, Naccarati, A.G., Zitvogel, V., Caldas, C., Engstrand, L., Loilbl, S., Fieschi, J., Heinzerling, L., Kroemer, G., and Zitvogel, L.

Abstract

Contains fulltext : 220857.pdf (Publisher’s version ) (Open Access), Accumulating evidence demonstrates the decisive role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade in preclinical tumor models, as well as in cancer patients. In synthesis, it appears that a normal intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. These findings have led to the design of clinical trials that evaluate the capacity of modulation of the gut microbiota to synergize with treatment and hence limit tumor progression. Along the lines of this Trial Watch, we discuss the rationale for harnessing the gut microbiome in support of cancer therapy and the progress of recent clinical trials testing this new therapeutic paradigm in cancer patients.

Published
2020

36. Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients

Author

Blanc-Durand, F., primary, Auclin, E., additional, Planchard, D., additional, Aix, S. Ponce, additional, Hendriks, L., additional, Sullivan, I.G., additional, Saravia, D., additional, Routy, B., additional, Castro, R. Lopez, additional, Pilotto, S., additional, Aboubakar, F., additional, Kassouf, E., additional, Rodriguez, A., additional, Martin, A. Amores, additional, Bluthgen, M.V., additional, Duchemann, B., additional, Caramella, C., additional, Nadal, E., additional, Besse, B., additional, and Mezquita, L., additional

Published
2019
Full Text
View/download PDF

37. Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155

Author

de Oliveira, A. Lepletier, primary, Madore, J., additional, O’donnell, J.S., additional, Johnston, R.L., additional, Eastgate, M., additional, Mallardo, D., additional, Ascierto, P.A., additional, Massi, D., additional, Merelli, B., additional, Mandala, M., additional, Wilmott, J.S., additional, Bald, T., additional, Stagg, J., additional, Routy, B., additional, Long, G.V., additional, Scolyer, R.A., additional, Waddell, N., additional, Dougall, W.C., additional, Teng, M.W.L., additional, and Smyth, M., additional

Published
2019
Full Text
View/download PDF

38. Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Blanc-Durand, F., Auclin, E., Planchard, D., Aix, S. Ponce, Hendriks, L., Sullivan, I.G., Saravia, D., Routy, B., Castro, R. Lopez, Pilotto, S., Aboubakar Nana, Frank, Kassouf, E., Rodriguez, A., Martin, A. Amores, Bluthgen, M.V., Duchemann, B., Caramella, C., Nadal, E., Besse, B., Mezquita, L., ESMO Immuno-Oncology Congress 2019, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Blanc-Durand, F., Auclin, E., Planchard, D., Aix, S. Ponce, Hendriks, L., Sullivan, I.G., Saravia, D., Routy, B., Castro, R. Lopez, Pilotto, S., Aboubakar Nana, Frank, Kassouf, E., Rodriguez, A., Martin, A. Amores, Bluthgen, M.V., Duchemann, B., Caramella, C., Nadal, E., Besse, B., Mezquita, L., and ESMO Immuno-Oncology Congress 2019

Abstract

BACKGROUND : The Lung Immune Prognostic Index (LIPI), combining the derived neutrophils/[leucocytes minus neutrophils] ratio (dNLR) and lactate dehydrogenase (LDH), has been associated with survival for ICI-single agent in large cohorts of refractory advanced NSCLC. However the role of LIPI in untreated NSCLC patients has not been explored yet. We assessed the value of LIPI in the front-line setting of advanced NSCLC patients (pts) treated with ICI-single agent or in combination with chemotherapy and compared to a cohort of pts treated exclusively with chemotherapy (CT). [...]

Published
2019

39. P1.04-01 Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PD1/PDL1 Immune Checkpoint Inhibitors

Author

Richard, C., primary, Elkrief, A., additional, Malo, J., additional, Cvetkovic, L., additional, Florescu, M., additional, Blais, N., additional, Tehfe, M., additional, Gagné, A., additional, Labbe, C., additional, Orain, M., additional, Joubert, P., additional, Ghiringhelli, F., additional, and Routy, B., additional

Published
2019
Full Text
View/download PDF

40. Cancer patient participation and compliance in microbiome sample collection: An oncology research nurse’s experience

Author

Malo, J., primary, Messaoudene, M., additional, Cauchois, F., additional, Belkaid, W., additional, Frizon-Peresa, D., additional, Ikene, S., additional, Rousseau, L., additional, Lattouf, J.-B., additional, Elkrief, A., additional, Mezquita, L., additional, Derosa, L., additional, Besse, B., additional, Blais, N., additional, Alameddine, R., additional, Tehfe, M., additional, Florescu, M., additional, and Routy, B., additional

Published
2019
Full Text
View/download PDF

43. Immuno-oncology-101: overview of major concepts and translational perspectives.

Author

Allard, Bertrand, Aspeslagh, Sandrine, Garaud, Soizic, Dupont, F A, Solinas, Cinzia, Kok, M, Routy, B, Sotiriou, Christos, Stagg, John, Buisseret, Laurence, Allard, Bertrand, Aspeslagh, Sandrine, Garaud, Soizic, Dupont, F A, Solinas, Cinzia, Kok, M, Routy, B, Sotiriou, Christos, Stagg, John, and Buisseret, Laurence

Abstract

Cancer immunotherapy is demonstrating impressive clinical benefit in different malignancies and clinical oncologists are increasingly turning their attention to immune-oncology. It is now well recognized that innate and adaptive immune cells infiltrating tumors are associated with clinical outcomes and responses to treatments, and can be harnessed to patients' benefit. Considerable advances have also been made in understanding how cancers escape from immune attack. Targeting of immunological escape processes regulated by the expression of immune checkpoint receptors and ligands and the down-modulation of tumor antigen presentation is the basis of immuno-oncology treatments. Despite recent achievements, there remain a number of unresolved issues in order to successfully implement cancer immunotherapy in many cancers. Importantly, clinical biomarkers are still needed for better optimization of emerging combination immunotherapies and better treatment tailoring. In this review, we summarize the function of innate and adaptive immune cells in anti-tumor immunity and the general mechanisms exploited by tumor cells to escape and inhibit immune responses as well as therapeutic strategies developed to overcome these mechanisms and discuss emerging biomarkers in immuno-oncology., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2018

48. 17P - Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients

Author

Blanc-Durand, F., Auclin, E., Planchard, D., Aix, S. Ponce, Hendriks, L., Sullivan, I.G., Saravia, D., Routy, B., Castro, R. Lopez, Pilotto, S., Aboubakar, F., Kassouf, E., Rodriguez, A., Martin, A. Amores, Bluthgen, M.V., Duchemann, B., Caramella, C., Nadal, E., Besse, B., and Mezquita, L.

Published
2019
Full Text
View/download PDF

50. Pulmonary Langerhans Cell Histiocytosis with Lytic Bone Involvement in an Adult Smoker: Regression following Smoking Cessation

Author

Routy, B., Hoang, J., and Gruber, J.

Subjects
Article Subject
Abstract

Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm characterized by the proliferation and dissemination of histiocytes. These in turn may cause symptoms ranging from isolated, infiltrative lesions to severe multisystem disease. Pulmonary Langerhans cell histiocytosis (PLCH) presents as a localized polyclonal proliferation of Langerhans cells in the lungs causing bilateral cysts and fibrosis. In adults, this rare condition is considered a reactive process associated with cigarette smoking. Recently, clonal proliferation has been reported with the presence of BRAF V600E oncogenic mutation in a subset of PLCH patients. Spontaneous resolution was described; however, based on case series, smoking cessation remains the most effective way to achieve complete remission and prevent long term complications related to tobacco. Herein, we report the case of an adult woman with biopsy-proven PLCH presenting with thoracic (T8) vertebral bone destruction. Both the lung and the bone diseases regressed following smoking cessation, representing a rare case of synchronous disseminated PCLH with bone localization. This observation underscores the contribution of cigarette smoking as a systemic trigger of both pulmonary and extrapulmonary bone lesions. A review of similar cases in the literature is also presented.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results